{
    "clinical_study": {
        "@rank": "114197", 
        "arm_group": {
            "arm_group_label": "MP-424", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "To conduct the following evaluations in Korean healthy male adult volunteers receiving a\n      single and multiple doses of MP-424 tablets:\n\n        -  Pharmacokinetics of MP-424 after a single and multiple doses.\n\n        -  Safety and tolerability of single and multiple doses of MP-424."
        }, 
        "brief_title": "Clinical Pharmacology Study of MP-424", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": "Chronic Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Korean healthy male volunteers aged 20 to 55 years\n\n        Exclusion Criteria:\n\n          -  Subjects with a BMI of <18.5 or >25.0, or body weight of <50kg at prior examination\n\n          -  Subjects who have had surgery that is known to affect gastrointestinal absorption of\n             drugs (except for appendectomy and hernia surgery)\n\n          -  Subjects who have had any evidence of cardiac disease at prior examination or who\n             have a previous history of cardiac disease\n\n          -  Subjects who are positive for HBs antigen, serologic tests for syphilis, HCV\n             antibody, or HIV antibody at prior examination\n\n          -  Subjects who have experienced symptoms of alcohol abuse or excessive alcohol\n             ingestion\n\n          -  Subjects who test positive on urinalysis for drug use (amphetamine, benzodiazepine,\n             barbiturates, cannabinoid, cocaine, opiates, and methadone) at prior examination\n\n          -  Subjects who do not agree to use a physical contraceptive method during the study\n             period\n\n          -  Subjects who do not agree to use contraceptive methods for 90 days after final\n             administration of the study drug\n\n          -  Subjects who have consumed grapefruit, Seville orange, star fruit, cranberry, or any\n             processed food containing these fruits within 7 days before the commencement of study\n             drug administration\n\n          -  Subjects who have consumed health foods containing St John's Wort within 2 weeks\n             before study drug administration"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "26", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01766167", 
            "org_study_id": "MP-424-K01"
        }, 
        "intervention": [
            {
                "arm_group_label": "MP-424", 
                "description": "Low", 
                "intervention_name": "MP-424", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MP-424", 
                "description": "Middle", 
                "intervention_name": "MP-424", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MP-424", 
                "description": "High", 
                "intervention_name": "MP-424", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MP-424", 
                "description": "Multiple", 
                "intervention_name": "MP-424", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Genotype 2", 
        "lastchanged_date": "April 2, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "Clinical Pharmacology Study of MP-424 in Healthy Male Adult Volunteers (Single- and Multiple-Dose Study)", 
        "overall_official": {
            "affiliation": "Mitsubishi Tanabe Pharma Corporation", 
            "last_name": "Kazuoki Kondo, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "MP-424 area under the plasma concentration-time curve (AUC) from 0 to infinity in Korean healthy volunteers", 
                "safety_issue": "No", 
                "time_frame": "up to 1 week"
            }, 
            {
                "measure": "Number of participants with adverse events as a measure of safety and tolerability in Korean healthy volunteers", 
                "safety_issue": "Yes", 
                "time_frame": "up to 2 week"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01766167"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Mitsubishi Tanabe Pharma Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mitsubishi Tanabe Pharma Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}